Article
Oncology
Natalie Y. L. Ngoi, Valerie Heong, Johann Tang, Bok Ai Choo, Nesaretnam Barr Kumarakulasinghe, Diana Lim, Mellisa Low, Siew Eng Lim, Yi Wan Lim, Yiat Horng Leong, Michelle Tseng, Pearl S. Y. Tong, Arunachalam Ilancheran, Jeffrey J. H. Low, Joseph Ng, Yee Liang Thian, Vicky Koh, David S. P. Tan
Summary: The study aimed to determine the recommended dose and efficacy of weekly paclitaxel with low-dose fractionated whole abdominal radiation therapy in platinum-resistant ovarian cancer patients. Encouraging efficacy was observed in heavily pretreated patients with a disease control rate of 66.7%, with four patients achieving durable disease control of >= 12 weeks.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Cardiac & Cardiovascular Systems
Lillian L. Tsai, Danielle M. Fitzgerald, Rong Liu, Jenny T. Korunes-Miller, Eliza Neal, Yin P. Hung, Samantha Bilton, Aaron Hata, Mark W. Grinstaff, Yolonda L. Colson
Summary: A PDX surgical resection model of non-small cell lung cancer was established in mice, and it was found that intraoperative placement of drug-loaded meshes significantly improved local disease treatment, suggesting a potential improvement in recurrence-free survival for early-stage non-small cell lung cancer patients.
ANNALS OF THORACIC SURGERY
(2023)
Article
Biophysics
Na Ying, Sisi Liu, Mengmeng Zhang, Jing Cheng, Linghuan Luo, Jiayi Jiang, Gaofan Shi, Shu Wu, Jun Ji, Haoyuan Su, Hongzhi Pan, Dongdong Zeng
Summary: Paclitaxel, an effective chemotherapeutic drug, has curative effects on a broad range of cancers. However, its clinical application is limited due to toxicity and solubility issues. Recent advances in developing novel paclitaxel-loaded nano delivery systems show great potential in improving its efficacy by enhancing solubility and reducing side effects.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2023)
Article
Engineering, Biomedical
Hui Xiong, Xiaoyan Liu, Zuohan Xie, Linyuan Zhu, Haipeng Lu, Cheng Wang, Jing Yao
Summary: By combining nanodrugs targeting the tumor microenvironment, this study enhances the efficacy of tumor vascular normalization treatment by inhibiting glycolysis in tumor cells and endothelial cells, leading to better antitumor effects.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Oncology
S. Sugawara, J-S Lee, J-H Kang, H. R. Kim, N. Inui, T. Hida, K. H. Lee, T. Yoshida, H. Tanaka, C-T Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C-J Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Summary: This international study evaluated nivolumab with bevacizumab and chemotherapy as a first-line treatment for nonsquamous NSCLC, showing significantly longer progression-free survival and higher objective response rates in the nivolumab group compared to the placebo group in the interim analysis. The incidence of severe treatment-related adverse events was comparable between the two groups.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michael Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne Giroux Leprieur, Nicolas Girard, Marie Ange Massiani, Paul Bore, Renaud Descourt, Julian Pinsolle, Solene Valery, Isabelle Monnet, Aurelie Swalduz, Claire Tissot, Pierre Fournel, Anne Baranzelli, Alexis B. Cortot, Chantal Decroisette
Summary: The PB combination as second-line or beyond treatment for non-squamous NSCLC has acceptable toxicity and clinically relevant efficacy, particularly for patients who have progressed after immunotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Chemistry, Physical
Longmeng Li, Aaron R. Lindstrom, Andrew C. Birkeland, Menghuan Tang, Tzu-Yin Lin, Yikai Zhou, Bai Xiang, Xiangdong Xue, Yuanpei Li
Summary: This study presents a novel strategy for deep tumor-penetrating nano-delivery, in which a porphyrin-doxorubicin-based nanoprodrug is optimized through PEGylations/crosslinks and co-administration of the targeting peptide iRGD. The optimized nanoprodrug demonstrates enhanced anti-cancer performance and improved tumor penetration in both animal models and human tissue samples. It is a promising approach to strengthen the clinical implementation of nanoprodrugs.
Article
Chemistry, Physical
Longmeng Li, Aaron R. Lindstrom, Andrew C. Birkeland, Menghuan Tang, Tzu-Yin Lin, Yikai Zhou, Bai Xiang, Xiangdong Xue, Yuanpei Li
Summary: Nanoprodrugs assembled by prodrugs hold promise for cancer treatment, but their stability and tumor-targeted delivery efficiency are challenging. In this study, a deep tumor-penetrating nano-delivery strategy was developed by optimizing a porphyrin-doxorubicin-based nanoprodrug through PEGylation/crosslinks and co-administration of targeting peptide iRGD. The optimized nanoprodrug showed enhanced accumulation and penetration in tumor vascular and tissue, improving therapeutic efficacy through both passive tumor targeting dependent and independent modes.
Article
Oncology
Chang-Lu Wang, Lan-Ting Gao, Chang-Xing Lyu, Qin Zhang, Wan-Qin Zeng, Wen-Tao Fang, Lei Zhu, Xiao-Long Fu
Summary: This study assessed the activity of Bevacizumab in combination with a routine chemotherapeutic regimen for advanced thymic epithelial tumors. The results showed that Paclitaxel and platinum plus Bevacizumab had promising effects with manageable toxicities in refractory or relapsed advanced TETs.
Article
Chemistry, Multidisciplinary
Yun-qiu Miao, Ming-shu Chen, Xin Zhou, Lin-miao Guo, Jing-jing Zhu, Rui Wang, Xin-xin Zhang, Yong Gan
Summary: Introduction of chitosan oligosaccharide (CSO) modification on liposomes enhances the delivery of chemotherapeutics to lung tumors, leading to improved therapeutic outcomes for lung cancer treatment.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Cell Biology
Xiaxia Niu, Ting Wu, Qishuang Yin, Xinsheng Gu, Gege Li, Changlong Zhou, Mei Ma, Li Su, Shu Tang, Yanan Tian, Ming Yang, Hongmei Cui
Summary: This study found that the PXR antagonist SPA70 can reduce resistance to paclitaxel in non-small cell lung cancer (NSCLC). The combination of PTX and SPA70 may be a potential novel treatment for taxane-resistant lung cancer.
Review
Cell Biology
Xingyu Chen, Yongyun Li, Tengteng Yao, Renbing Jia
Summary: Zebrafish are widely used in cancer research due to their low cost, quick establishment, and small sample size required. The zebrafish patient-derived xenograft (zPDX) models show promising evidence for short-term clinical treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Wei Zheng, Tianchuan Zhu, Lantian Tang, Zhijian Li, Guanmin Jiang, Xi Huang
Summary: We engineered T cell-derived exosomes expressing the chimeric antigen receptor (CAR-Exos) to target mesothelin-expressing lung cancer. By delivering paclitaxel (PTX) encapsulated in CAR-Exos via inhalation to a mouse model, the tumor size was reduced and survival time was prolonged. In addition, PTX@CAR-Exos reshaped the tumor microenvironment and reversed immunosuppression.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Xiangjun Chen, Huayu He, Xinyu Guo, Mingyi Hou, Xinzhong Zhang, Shengnan Li, Changrong Wang, Guodong Zhao, Wenting Li, Xiuping Zhang, Wei Hong
Summary: This study developed highly effective pH-responsive and biodegradable nanoparticles that can deliver drugs to tumor sites through the enhanced permeability and retention effect. The nanoparticles showed a switchable charge and excellent drug loading efficiency. In vitro and in vivo experiments demonstrated the effectiveness and safety of this drug delivery system, resulting in a significant inhibition of tumor growth.
MOLECULAR PHARMACEUTICS
(2023)
Editorial Material
Medicine, General & Internal
Oladapo O. Yeku, Dan L. Longo
Summary: This editorial discusses the scientific basis of a clinical trial conducted by Prager and colleagues, which tested the efficacy of trifluridine-tipiracil and bevacizumab in treating patients with refractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)